WO2000059515A3 - Immunomodulating polymers - Google Patents

Immunomodulating polymers Download PDF

Info

Publication number
WO2000059515A3
WO2000059515A3 PCT/US2000/008586 US0008586W WO0059515A3 WO 2000059515 A3 WO2000059515 A3 WO 2000059515A3 US 0008586 W US0008586 W US 0008586W WO 0059515 A3 WO0059515 A3 WO 0059515A3
Authority
WO
WIPO (PCT)
Prior art keywords
secretion
inducing
methods
abscess formation
formation
Prior art date
Application number
PCT/US2000/008586
Other languages
French (fr)
Other versions
WO2000059515A2 (en
WO2000059515A9 (en
Inventor
Arthur O Tzianabos
Dennis L Kasper
Andrew B Onderdonk
Ying Wang
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Priority to AU40563/00A priority Critical patent/AU781950B2/en
Priority to EP00919958A priority patent/EP1169045A2/en
Priority to BR0009531-1A priority patent/BR0009531A/en
Priority to JP2000609078A priority patent/JP2002541113A/en
Priority to CA002366895A priority patent/CA2366895A1/en
Priority to MXPA01009930A priority patent/MXPA01009930A/en
Publication of WO2000059515A2 publication Critical patent/WO2000059515A2/en
Publication of WO2000059515A3 publication Critical patent/WO2000059515A3/en
Publication of WO2000059515A9 publication Critical patent/WO2000059515A9/en
Priority to AU2005201963A priority patent/AU2005201963B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2

Abstract

Methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. The methods of the invention are accomplished using an immunomodulator which is a polymer having at least two repeating charge motifs separated by at least a certain minimum distance.
PCT/US2000/008586 1999-04-02 2000-03-31 Immunomodulating polymers WO2000059515A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU40563/00A AU781950B2 (en) 1999-04-02 2000-03-31 Immunomodulating polymers
EP00919958A EP1169045A2 (en) 1999-04-02 2000-03-31 Immunomodulating polymers
BR0009531-1A BR0009531A (en) 1999-04-02 2000-03-31 Immunomodulation polymers
JP2000609078A JP2002541113A (en) 1999-04-02 2000-03-31 Immunomodulating polymer
CA002366895A CA2366895A1 (en) 1999-04-02 2000-03-31 Immunomodulating polymers
MXPA01009930A MXPA01009930A (en) 1999-04-02 2000-03-31 Immunomodulating polymers.
AU2005201963A AU2005201963B2 (en) 1999-04-02 2005-05-10 Immunomodulating polymers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12758499P 1999-04-02 1999-04-02
US16245799P 1999-10-29 1999-10-29
US60/127,584 1999-10-29
US60/162,457 1999-10-29

Publications (3)

Publication Number Publication Date
WO2000059515A2 WO2000059515A2 (en) 2000-10-12
WO2000059515A3 true WO2000059515A3 (en) 2001-01-11
WO2000059515A9 WO2000059515A9 (en) 2002-08-29

Family

ID=26825761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008586 WO2000059515A2 (en) 1999-04-02 2000-03-31 Immunomodulating polymers

Country Status (8)

Country Link
EP (1) EP1169045A2 (en)
JP (2) JP2002541113A (en)
CN (1) CN1362880A (en)
AU (1) AU781950B2 (en)
BR (1) BR0009531A (en)
CA (1) CA2366895A1 (en)
MX (1) MXPA01009930A (en)
WO (1) WO2000059515A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2003000753A (en) 2000-12-05 2003-06-16 Brigham & Womens Hospital USE OF ZWITTERIONIC POLYSACARIDS FOR THE SPECIFIC MODULATION OF IMMUNE PROGRESS
WO2003066053A1 (en) * 2002-02-07 2003-08-14 Rutgers, The State University Antibiotic polymers
US7629313B2 (en) 2002-03-08 2009-12-08 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathologies
US20040219160A1 (en) * 2003-03-31 2004-11-04 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
JP2011503104A (en) * 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー Immunomodulatory compounds and related compositions and methods
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
ES2694100T3 (en) 2010-04-07 2018-12-18 California Institute Of Technology Vehicle to distribute a compound in a mucous membrane and compositions, procedures and related systems
EP2731617A4 (en) * 2011-07-12 2015-07-01 Brigham & Womens Hospital Lipid-containing psa compositions, methods of isolation and methods of use thereof
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
JP6206916B2 (en) * 2013-11-15 2017-10-04 国立研究開発法人物質・材料研究機構 Intercellular signal transduction molecule production signal-inducing functional polymer and synthesis method thereof
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CA2997211A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
EP3533871A4 (en) * 2016-10-27 2020-05-06 Chang Gung Memorial Hospital, Linkou Method for evaluating risk of drug hypersensitivity reaction induced by sulfamethoxazole and/or trimethoprim
JP6789420B2 (en) * 2018-03-29 2020-11-25 三菱電機ビルテクノサービス株式会社 Heating device, heating method, and refrigerant recovery method
WO2019189769A1 (en) * 2018-03-30 2019-10-03 味の素株式会社 Cell growth composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704389A1 (en) * 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Process for the preparation of lymphokines by induction of lymphoid cells
WO1996007427A1 (en) * 1994-09-02 1996-03-14 Brigham And Women's Hospital, Inc. Capsular polysaccharide immunomodulator
WO1996032119A1 (en) * 1995-04-14 1996-10-17 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of gvhd

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704389A1 (en) * 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Process for the preparation of lymphokines by induction of lymphoid cells
WO1996007427A1 (en) * 1994-09-02 1996-03-14 Brigham And Women's Hospital, Inc. Capsular polysaccharide immunomodulator
WO1996032119A1 (en) * 1995-04-14 1996-10-17 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of gvhd

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. TZIANABOS ET AL.: "T CELL ACTIVATION BY ZWITTERIONIC POLYSACCHARIDES AND PEPTIDE MIMETICS PREVENTS ANTRABDOMINAL ABSCESS FORMATION.", ABSTRACTS OF THE 99 TH GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, CHICAGO, US, MAY 30-JUNE 3, 1999, vol. 99, - 3 June 1999 (1999-06-03), WASHINGTON, US, pages 37 - 38, XP002150694 *
A.O. TZIANABOS ET AL.: "STRUCTURAL CHARACTERISTICS OF POLYSACCHARIDES THAT INDUCE PROTECTION AGAINST INTR-ABDOMINAL ABSCESS FORMATION.", INFECTION AND IMMUNITY, vol. 62, no. 11, November 1994 (1994-11-01), WASHINGTON, US, pages 4881 - 4886, XP002150692 *
V.K. PERUMAL ET AL.: "PROTECTIVE EFFECT OF INTERLEUKIN-2 ON EXPERIMENTAL INTRA-ABDOMINAL ABSCESS DEVELOPMENT DUE TO BACTEROIDES FRAGILIS.", CLINICAL RESEARCH, vol. 38, no. 2, 1990, NEW YORK, N.Y., US, pages 550A, XP000952900 *
W.M. KALKA-MOLL ET AL.: "BACTEROIDES FRAGILIS NCTC 9343 CAPSULAR POLYSACCHARIDE PS A AND THE EFFECT OF CHAIN LENGHT ON T CELL PROLIFERATION.", ABSTRACTS OF THE 98 TH GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, ATLANTA, US, MAY 17-21, 1998, vol. 98, 1998, WASHINGTON, US, pages 123, XP002150693 *

Also Published As

Publication number Publication date
WO2000059515A2 (en) 2000-10-12
BR0009531A (en) 2001-12-26
AU781950B2 (en) 2005-06-23
MXPA01009930A (en) 2003-07-14
EP1169045A2 (en) 2002-01-09
WO2000059515A9 (en) 2002-08-29
AU4056300A (en) 2000-10-23
CN1362880A (en) 2002-08-07
CA2366895A1 (en) 2000-10-12
JP2011121986A (en) 2011-06-23
JP2002541113A (en) 2002-12-03

Similar Documents

Publication Publication Date Title
WO2000059515A3 (en) Immunomodulating polymers
AU2003216592A1 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
EP1389599A3 (en) Passive media separating device
AU2003245977A1 (en) Method for the preparation of olefin polymerisation catalysts
AU4370396A (en) Gram negative bacterial infection vaccine
AU2003239936A1 (en) System for scoring scanned test answer sheets
AU6294500A (en) Method for the production of an immunostimulant milk product and uses thereof
WO2000025815A8 (en) Novel immunoadjuvants
AU2003217685A1 (en) Immunomodulatory polymeric antigens for treating inflammatory pathogies
WO1999040938A3 (en) Vaccines comprising interleukin-12 and herpes simplex viral antigen
WO2002075507A3 (en) Anti-bacterial vaccine compositions
WO2003022306A3 (en) Bacterial vaccine
WO2003092615A3 (en) Use of anti-cd1 antibodies for the modulation of immune responses
CA2215520A1 (en) Chlamydia vaccines
EP1946767A3 (en) Autologous T-cell vaccines against multiple sclerosis
AU8580298A (en) Artificial system for the production of infectious human papillomavirus
AU5741699A (en) Low-molecular fragments of hyaluronic acid for the preparation of vaccines
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
AU2003266884A1 (en) Accelerating recovery from trauma
AU2003234689A1 (en) Selective acylation of secondary hydroxyl groups
AU2587688A (en) Recovery of titanium dioxide from fines such as blow over dust, cyclone solids etc
AU1332997A (en) Ophthalmic composition comprising polyoxyethylene-polyoxypropylene polymers
AU2003239151A1 (en) Compositions and methods for the acceleration of protein secretion dynamics
AU2002952817A0 (en) Method for the detection of newly acquired hiv infection
AU2003225057A1 (en) Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00805847.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/973/KOL

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2366895

Country of ref document: CA

Ref document number: 2366895

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009930

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 609078

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000919958

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000919958

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 8/10, DRAWINGS, REPLACED BY A NEW PAGE 8/10; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY; PAGES 1/10-7/10 AND 9/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/10-7/10 AND 9/10-10/10

WWW Wipo information: withdrawn in national office

Ref document number: 2000919958

Country of ref document: EP